In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...

Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model. Assessing genomic instability (GI) by shallow whole-genome ...

Urological malignancies, including prostate, bladder, renal, and testicular cancers, represent a major global health burden and display remarkable ...

If you’ve recently been diagnosed with prostate cancer, or if you’ve had a prostate biopsy to test for prostate cancer, you might have seen the term “Gleason score” or “Gleason grade” on the pathology ...

Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted Breakthrough Device Designation by the FDA for its ArteraAI Prostate, an AI-enabled tool ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304). This is an ASCO Meeting Abstract ...

Human tissue is intricate, complex and, of course, three dimensional. But the thin slices of tissue that pathologists most often use to diagnose disease are two dimensional, offering only a limited ...